Compare Marriott International Inc (MAR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs GeneDx Holdings Corp — how do they compare? Marriott International Inc trades at $360.95 (market cap $94.16B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Marriott International Inc is far larger — about 46.6× GeneDx Holdings Corp's market cap, and Marriott International Inc pays a 0.81% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and GeneDx Holdings Corp for 19 Days on average.
| MAR | WGS | |
|---|---|---|
Market Cap | $94.16B | $2.02B |
Volume | 996,176 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $167.51 |
52-Week Low | $259.04 | $34.51 |
Typical Hold Time | 164 Days | 19 Days |
Enterprise Value | $111.47B | $2.05B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.50, down 1.32% on the day, with a bullish technical signal from moving averages and support near $354. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%, though the P/E of 36.9 suggests a premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share payable in September 2026. Analyst consensus is a Buy with a $386.71 price target, indicating potential upside.
The outlook for MAR is positive, supported by strong travel demand and strategic partnerships, but risks include high debt levels and sensitivity to economic cycles. With institutional interest mixed and a neutral sentiment from oscillators, the stock offers growth potential tempered by valuation concerns and macroeconomic headwinds.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
